A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
BackgroundThe development of a medicine is not only underpinned by good science but also by Quality DecisionMaking Practices (QDMPs). Indeed, it is important to ensure that all organisations involved in the lifecycle of medicines are aligning their practices in decision-making to the QDMPs to ensure...
Saved in:
Main Authors: | Magdalena Bujar (Author), Neil McAuslane (Author), Stuart Walker (Author), Sam Salek (Author) |
---|---|
Format: | Book |
Published: |
Kerman University of Medical Sciences,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
by: Magdalena Bujar, et al.
Published: (2019) -
The development and validation of a generic instrument, QoDoS, for assessing the quality of decision making
by: Ronan Donelan, et al.
Published: (2016) -
A practical approach to communicating benefit-risk decisions of medicines to stakeholders
by: James eLeong, et al.
Published: (2015) -
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
by: Nicola Allen, et al.
Published: (2017) -
An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017-2018 using the OpERA methodology
by: Lawrence Liberti, et al.
Published: (2020)